vTv Therapeutics Q3 2026 net loss widens 34% to $11.62 million

PUBT · 21h ago
vTv Therapeutics Q3 2026 net loss widens 34% to $11.62 million
  • vTv Therapeutics’ third-quarter 2026 net loss attributable to shareholders widened 34% year-over-year to $11.62 million.
  • General and administrative expenses rose 33% to $4.9 million on higher share-based compensation and payroll-related expenses.
  • Cash totaled $77.16 million at September 30, 2026, expected to fund operations well through the anticipated CATT1 topline readout.
  • Phase 3 CATT1 enrollment completed in October with 166 participants randomized; topline results for the type 1 diabetes treatment are expected mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. vTv Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051601PRIMZONEFULLFEED9869698) on November 05, 2026, and is solely responsible for the information contained therein.